期刊
IMMUNOLOGY
卷 167, 期 2, 页码 124-138出版社
WILEY
DOI: 10.1111/imm.13526
关键词
adjuvants; immunization routes; mucosal immunity; mucosal surfaces; vaccine
类别
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [131412/2019-1]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [001]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [19/02042-9, 12/15568-0, 18/17945-1]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [12/15568-0, 19/02042-9] Funding Source: FAPESP
Vaccines are crucial in controlling infectious diseases, but most vaccines are not effective in providing mucosal protection. More research is needed to develop vaccines that can elicit mucosal immunity and provide protection at the first site of contact with pathogens.
Vaccines are the most effective tool to control infectious diseases, which provoke significant morbidity and mortality rates. Most vaccines are administered through the parenteral route and can elicit a robust systemic humoral response, but they induce a weak T-cell-mediated immunity and are poor inducers of mucosal protection. Considering that most pathogens enter the body through mucosal surfaces, a vaccine that elicits protection in the first site of contact between the host and the pathogen is promising. However, despite the advantages of mucosal vaccines as good options to confer protection on the mucosal surface, only a few mucosal vaccines are currently approved. In this review, we discuss the impact of vaccine administration in different mucosal surfaces; how appropriate adjuvants enhance the induction of protective mucosal immunity and other factors that can influence the mucosal immune response to vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据